Clinical trials open for the enrollment


Title: MITO 35b – “Olaparib Beyond Progression Compared to Platinum Chemotherapy After Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer Patients”

 

At present, PARP-inhibitors cannot be used more than once. This study gives the opportunity to use olaparib as maintenance after secondary cytoreductive surgery and platinum-based chemotherapy after previous treatment with PARP-inhibitors.

 

Principal Investigator: Prof. Pierosandro Tagliaferri

 

For enrollment information please contact: Dr. Luigia Gervasi (Tel: +39 0961-3647921) Email: luigiagervasi@gmail.com


Title: CA043-001 – An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers

 

Phase 1/2 first-in-human trial that investigates role of BMS-986288 (a modified form of ipilimumab), alone or in association to nivolumab, in various tumors.

 

Principal Investigator: Prof. Pierfrancesco Tassone

 

For enrollment information please contact: Dr. Luigia Gervasi (Tel: 0961-3647921) Email: luigiagervasi@gmail.com

 


Clinical trials closed for the enrollment

Title: MITO 31 – “Olaparib in Patients With Recurrent Ovarian Cancer Wild Type for Germline and Somatic BRCA 1 and 2 Genes: The MITO 31 Translational Study”

Principal Investigator: Prof. Pierosandro Tagliaferri


Title: ROME – “The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy”

Principal Investigator: Prof. Pierosandro Tagliaferri